Utility and sensitivity of the sore throat pain model: Results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib

Journal of Clinical Pharmacology

Volumn 47, Issue 7, 2007, Pages 860-870

  Schachtel, Bernard P ^a,c   Pan, Sharon ^a,b   Kohles, Joseph D ^a,b   Sanner, Kathleen M ^a   Schachtel, Emily P ^a   Bey, Mary ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pfizer Global Pharmaceuticals   (United States)

^c Schachtel Research Company   (United States)

Author keywords

Acute pain model; Assay sensitivity; COX 2 selective inhibitor; Individual responder rate; Pharyngitis; Placebo; Sore throat; Valdecoxib

Indexed keywords

PLACEBO; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISOXAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSITIVITY ANALYSIS; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BIOLOGICAL MODEL; MIDDLE AGED; PAIN; PAIN ASSESSMENT; PHARYNGITIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PAIN; PAIN MEASUREMENT; PHARYNGITIS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 34548008829     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007301621     Document Type: Article

References (55)

1. Hodgkin K. Towards Earlier Diagnosis in Primary Care. Edinburgh, UK: Churchill Livingstone; 1978.
2. Lamberts H, Woods M. ICPC: International Classification of Primary Care. Oxford, UK: Oxford University Press; 1987.
3. Vincent MT, Celestin N, Hussain AN. Pharyngitis. Am Fam Physician. 2004;69:1465-1470.
4. Schachtel BP, Fillingim JM, Thoden WR, et al. Sore throat pain in the evaluation of mild analgesics. Clin Pharmacol Ther. 1988; 44:704-711.
5. Schachtel BP, Fillingim JM, Beiter DJ, Lane AC, Schwartz LA. Rating scales for analgesics in sore throat. Clin Pharmacol Ther. 1984;36:151-156.
6. Schachtel BP. Sore throat pain. In: Portenoy MM, Laska E, eds. Advances in Pain Research and Therapy. New York: Raven; 1991.
7. Beaver WT. Measurement of analgesic efficacy in man. In: Bonica JJ, Lindblom U, Iggo A, eds. Advances in Pain Research and Therapy. Vol.5. New York: Raven; 1983.
8. Lasagna L. The clinical measurement of pain. Ann N Y Acad Sci. 1960;86:28-37.
9. 9. Wallenstein SL. Measurement of pain and analgesia in cancer patients. Cancer. 1984;53(10 suppl):2260-2266. (Pubitemid 14136879)
10. 10. Cooper SA, Schachtel BP, Goldman E, Gelb S, Cohn P. Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 1989; 29:1026-1030. (Pubitemid 20038084)
11. Schachtel BP, Fazio RC, Greene JJ. Ibuprofen 400 mg compared to acetaminophen 600 mg with codeine 60 mg for pain relief following periodontal surgery. J Clin Pharm. 1990;30:846.
12. Schachtel BP, Fillingim JM, Lane AC, Thoden WR, Baybutt RI. Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med. 1991;151:733-737.
13. Schachtel BP, Cleves GS, Konerman JP, Brown AT, Markham AO. A placebo-controlled model to assay the onset of action of nonprescription- strength analgesic drugs. Clin Pharmacol Ther. 1994;55:464-470.
14. 14. Schachtel BP, Homan HD, Gibb IA, Christian J. Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. Clin Pharmacol Ther. 2002;71:375-380. (Pubitemid 34518148)
15. Konerman HJ, Schachtel BP, Thoden WR. Sensory qualities of pain in the evaluation of sore throat. Clin Pharmacol Ther. 1990; 47:188.
16. Bertin L, Pons G, d'Athis P, et al. Randomized, double-blind, multicenter, controlled trial of ibuprofen versus acetaminophen (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children. J Pediatr. 1991;119:811-814.
17. Schachtel BP, Thoden WR. A placebo-controlled model for assaying systemic analgesics in children. Clin Pharmacol Ther. 1993;53:593-601.
18. Schachtel BP, Paggiarino DA. A randomized, double-blind, placebo-controlled model demonstrating the topical effect of benzydamine in children with sore throat. Clin Pharmacol Ther. 1996;59:146.
19. 19. Boureau F, Pelen F, Verriere F, et al. Evaluation of ibuprofen vs. paracetamol analgesic activity using a sore throat pain model. Clin Drug Invest. 1999;17:1-8. (Pubitemid 29055863)
20. Benrimoj SI, Langford JH, Homan HD. Efficacy and safety of the anti-inflammatory throat lozenge flurbiprofen 8.75 mg in the treatment of sore throat. Fundam Clin Pharmacol. 1999;13:189.
21. 21. Watson N, Nimmo WS, Christian J, Charlesworth A, Speight J, Miller K. Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebocontrolled study of efficacy and safety. Int J Clin Pharm. 2000; 54:490-496. (Pubitemid 30848060)
22. 22. Weckx LL, Ruiz JE, Duperly J, et al. Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac. / Int Med Res. 2002; 30:185-194. (Pubitemid 34467449)
23. Food and Drug Administration, Department of Health and Human Services Public Health Service. CDER OTC Analgesic Policy Change. Memorandum to the Commissioner, Food and Drug Administration from the Director, Center for Drug Evaluation. Available at: http:// www.fda.gov/ohrms/dockets/ac/02/briefing/ 3873B1-03-OTC%20Cri teria.doc. Accessed 1994.
24. European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. Available at: http://www.emea.eu.int/pdfs/human/ewp/061200en. pdf. Accessed October 11, 2006.
25. 25. Simon LS. Nonsteroidal anti-inflammatory drugs and their effects: the importance of COX2 selectivity. J Clin Rheumatol. 1996; 2:135-140. (Pubitemid 26240786)
26. Gierse JK, McDonald JJ, Hauser SD, et al. A single amino acid difference between cyclooxygenase-1 (COX-I) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996;271:15810-15814.
27. 27. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol4- yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000;43:775-777. (Pubitemid 30152286)
28. 28. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. JFam Pinct. 2002;51: 530-537. (Pubitemid 34602987)
29. 29. Makarowski W, Zhao W, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of Osteoarthritis of the hip: a randomized, double-blind, placebocontrolled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290-296. (Pubitemid 34467633)
30. 30. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology. 2002;41:1008-1016. (Pubitemid 35049930)
31. 31. Daniels S, Talwalker S, Torri S, et al. Valdecoxib, a COX-2 specific inhibitor, is effective and well tolerated in treating women with primary dysmenorrhea. Obstet Gynecol. 2002;100:350-358. (Pubitemid 34874802)
32. Schachtel BP, Fillingim JM, Beiter DJ, Lane AC, Schwartz LA. Subjective and objective features of sore throat. Arch Intern Med. 1984;144:497-500.
33. Schachtel BP, Kohles JD, Pan S, Sanner KM. The Lasagna Pain Scale. Clin Pharmacol Ther. 2005;77:93.
34. Beecher H, Keats A, Mosteller F, Lasagna L. The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo "reactors" and "non-reactors." J Pharmacol Exp Ther. 1953;109:393-400.
35. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
36. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287-294.
37. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
38. 38. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003;105:151-157. (Pubitemid 37162484)
39. McQuay HJ, Edwards JE, Moore RA. Evaluating analgesia: the challenges." Am J Ther. 2002;9:179-187.
40. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644-R665.
41. 41. Moore RA, Edwards JE, McQuay H. Acute pain: individual patients meta-analysis shows the impact of different ways of analyzing and presenting results. Pain. 2005;116:322-331. (Pubitemid 40957136)
42. 42. Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain. 1996;66:229-237. (Pubitemid 26283992)
43. 43. Moore RA, Moore O, Quay H, et al. Deriving dichotomous outcome measures from continuous data in randomized controlled trials of analgesics: use of pain intensity and visual analog scales. Pain. 1997;69:311-315. (Pubitemid 27096413)
44. Cooper SA. Single-dose analgesic studies: the upside and downside of assay sensitivity. In: Max MB, Portenoy RK, Laska EM, eds. Advances in Pain Research and Therapy: The Design of Analgesic Clinical Trials. Vol.18. New York: Raven; 1991.
45. Schachtel BP, Paggiarino DA, Crockett S. The transitional scale: a direct indicator of change in status. Clin Pharmacol Ther. 1998;63:173.
46. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
47. Melzack R, Torgerson WS. On the language of pain. Anesthesiology. 1971;34:50-59.
48. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79:231-252.
49. 49. Barden J, Edwards JE, Mason L, McQuay HJ, Moore RA. Outcomes in acute pain trials: systematic review of what was reported? Pain. 2004;109:351-356. (Pubitemid 38638712)
50. Lasagna L. Placebos and controlled trials under attack. Eur J Clin Pharmacol. 1979;15:373-374.
51. Lasagna L. The placebo effect. J Allergy Clin Immunol. 1986; 78:161-165.
52. Schachtel BP, Thoden WR, Baybutt RI. Ibuprofen and acetaminophen in the relief of post-partum episiotomy pain. J Clin Pharmacol. 1989;29:550-553.
53. 53. Schachtel BP, Furey SA, Thoden WR. Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache. J Clin Pharmacol. 1996;36:1120-1125. (Pubitemid 27056939)
54. Schachtel BP, Sanner KM, Meskin NA, Bey M. Patients' criteria for meaningful relief to determine onset of action. Clin Pharmacol Ther. 2005;77:P51.
55. 55. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anestheslol. 2003;3:1. (Pubitemid 38751145)